ERBB2 and breast carcinoma: Based on the results of the PALOMA-1/TRIO 18 study, palbociclib received accelerated approval in combination with letrozole for first line therapy for post-menopausal women with advanced HR positive, HER2 negative breast cancer and subsequent therapy after progression on prior endocrine therapy (51).